FDA – Comments submitted to FDA on Rare Diseases: Common Issues in Drug Development

Regulatory Comments

Comments submitted to FDA on Rare Diseases: Common Issues in Drug Development.(Docket Number: FDA-2015-D-2818-0001).

Click here to read the comments and impact on ACRP Members.

Related

FDA – Comments submitted regarding Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”)

FDA – Comments submitted regarding Clinical Outcome Assessment Compendium

CIOMS – Comments submitted regarding the public consultation on the Revision of CIOMS 2002 International Ethical Guidelines for Biomedical Research Involving Human Subjects